These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16195627)

  • 21. Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
    Wilson AM; Brittenden J; Bachoo P; Ford I; Nixon GF
    J Vasc Surg; 2009 Oct; 50(4):861-9. PubMed ID: 19786240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty.
    Tsutsui M; Shimokawa H; Higuchi S; Yoshihara S; Hayashida K; Sobashima A; Kuga T; Matsuguchi T; Okamatsu S
    Jpn Circ J; 1996 Apr; 60(4):207-15. PubMed ID: 8726169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cilostazol is associated with improved outcomes after peripheral endovascular interventions.
    Warner CJ; Greaves SW; Larson RJ; Stone DH; Powell RJ; Walsh DB; Goodney PP
    J Vasc Surg; 2014 Jun; 59(6):1607-14. PubMed ID: 24468286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percutaneous revascularization of femoropopliteal artery disease: PTA and PTA plus stent. Results after six years' follow-up.
    Pozzi Mucelli F; Fisicaro M; Calderan L; Malacrea M; Mazzone C; Cattin L; Scardi S; Pozzi Mucelli R
    Radiol Med; 2003 Apr; 105(4):339-49. PubMed ID: 12835627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis.
    Kamishirado H; Inoue T; Mizoguchi K; Uchida T; Nakata T; Sakuma M; Takayanagi K; Morooka S
    Am Heart J; 2002 Aug; 144(2):303-8. PubMed ID: 12177649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In Vivo Quantification of the Deformations of the Femoropopliteal Segment: Percutaneous Transluminal Angioplasty vs Nitinol Stent Placement.
    Gökgöl C; Schumann S; Diehm N; Zheng G; Büchler P
    J Endovasc Ther; 2017 Feb; 24(1):27-34. PubMed ID: 28095767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
    Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
    Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial.
    Suh JW; Lee SP; Park KW; Lee HY; Kang HJ; Koo BK; Cho YS; Youn TJ; Chae IH; Choi DJ; Rha SW; Bae JH; Kwon TG; Bae JW; Cho MC; Kim HS
    J Am Coll Cardiol; 2011 Jan; 57(3):280-9. PubMed ID: 21232664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of cilostazol versus ticlopidine therapy after stent implantation.
    Park SW; Lee CW; Kim HS; Lee HJ; Park HK; Hong MK; Kim JJ; Park SJ
    Am J Cardiol; 1999 Sep; 84(5):511-4. PubMed ID: 10482146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Dose Paclitaxel-Coated Versus Uncoated Percutaneous Transluminal Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease: One-Year Results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon).
    Schroeder H; Werner M; Meyer DR; Reimer P; Krüger K; Jaff MR; Brodmann M;
    Circulation; 2017 Jun; 135(23):2227-2236. PubMed ID: 28424223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis.
    Kawamura Y; Ishii H; Aoyama T; Tanaka M; Takahashi H; Kumada Y; Toriyama T; Murohara T
    J Vasc Surg; 2009 Nov; 50(5):1057-62. PubMed ID: 19782527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and 1-year revascularization outcome of SilverHawk atherectomy in treating in-stent restenosis of femoropopliteal arteries: a retrospective review from a single center.
    Shammas NW; Shammas GA; Helou TJ; Voelliger CM; Mrad L; Jerin M
    Cardiovasc Revasc Med; 2012; 13(4):224-7. PubMed ID: 22575073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis.
    Armstrong EJ; Thiruvoipati T; Tanganyika K; Singh GD; Laird JR
    J Endovasc Ther; 2015 Aug; 22(4):506-13. PubMed ID: 26130385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
    Jang JS; Jin HY; Seo JS; Yang TH; Kim DK; Kim DS; Kim DK; Seol SH; Kim DI; Cho KI; Kim BH; Park YH; Je HG; Jeong YH; Kim WJ; Lee JY; Lee SW
    Cardiology; 2012; 122(3):133-43. PubMed ID: 22832424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superiority of stent-grafts for in-stent restenosis in the superficial femoral artery: twelve-month results from a multicenter randomized trial.
    Bosiers M; Deloose K; Callaert J; Verbist J; Hendriks J; Lauwers P; Schroë H; Lansink W; Scheinert D; Schmidt A; Zeller T; Beschorner U; Noory E; Torsello G; Austermann M; Peeters P
    J Endovasc Ther; 2015 Feb; 22(1):1-10. PubMed ID: 25775672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
    Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
    J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intraarterial (192)Ir high-dose-rate brachytherapy for prophylaxis of restenosis after femoropopliteal percutaneous transluminal angioplasty: the prospective randomized Vienna-2-trial radiotherapy parameters and risk factors analysis.
    Pokrajac B; Pötter R; Maca T; Fellner C; Mittlböck M; Ahmadi R; Seitz W; Minar E
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):923-31. PubMed ID: 11072147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.